# US 2022/0033491 A1 · Combination therapy of cldn18 antibody and chemotherapy drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033491 A1
- Document ID: US20220033491A1
- Status: Published application
- Kind: A1
- Application number: 17/281,372
- Filed: 2019-09-29
- Published: 2022-02-03
- Earliest claimed: 2018-09-30
- Applicants: Cafa Therapeutics Limited
- Inventors: Zonghai LI; Huamao WANG
- Web page: https://patentgrep.com/patent/US20220033491A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating CLDN18-positive tumors, wherein an antibody that specifically recognizes CLDN18 and chemotherapy drugs are administered to a subject in need thereof. The chemotherapy drugs comprise: 5-fluorouracil, a prodrug thereof, or an active metabolite thereof, and oxaliplatin, a prodrug thereof, or an active metabolite thereof; or 5-fluorouracil, a prodrug thereof, or an active metabolite thereof, oxaliplatin, a prodrug thereof, or an active metabolite thereof, and a taxane drug. A kit combination for treating CLDN18 positive tumors. Compared with the existing technology, the treatment method and the kit combination have greatly enhanced tumor suppression rates and better anti-tumor effects. In addition, the present invention may reduce the use of chemotherapy drugs, and improve the safety of medication and improve tolerance of patients.

## Claims

### Claim 1

A method for treating a CLDN18-positive tumors, comprising administering an antibody that specifically recognize CLDN18 and a chemotherapeutic drug to an individual in need thereof, and the chemotherapeutic drug is:
5-fluorouracil or a prodrug or active metabolite thereof, and oxaliplatin or a prodrug or active metabolite thereof; or 5-fluorouracil or a prodrug or active metabolite thereof, oxaliplatin or a prodrugs or active metabolite thereof and taxanes;
preferably, the chemotherapeutic drug is:
5-fluorouracil or a prodrug thereof, and oxaliplatin or a prodrug thereof; or 5-fluorouracil or a prodrug thereof, oxaliplatin or a prodrug thereof and taxanes;
more preferably, the prodrug of 5-fluorouracil is capecitabine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody specifically recognizes CLDN 18.2, instead of CLDN 18.1.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the chemotherapeutic drug and the antibody against CLDN18 are administered without a particular order.

### Claim 4 (depends on 3)

The method of claim 3, wherein the chemotherapeutic drug is administered, and then the antibody against CLDN18 is administered.

### Claim 5 (depends on 4)

The method of claim 4, wherein the chemotherapeutic drug and the antibody against CLDN18 are administered on the same day; or the antibody against CLDN18 is administered at least one day after the chemotherapeutic drug is administered.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of the antibody against CLDN18 is 500-1200 mg/m2/time; preferably, 500-1000 mg/m2/time; more preferably, 500-900 mg/m2/time; and the most preferably, 600-800 mg/m2/time.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of the antibody against CLDN18 is 20-300 mg/kg/time; preferably, 20-100 mg/kg/time; and more preferably, 20-50 mg/kg/time.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of 5-fluorouracil or a prodrug or active metabolite thereof is 300-900 mg/m2/time;
and preferably, 5-fluorouracil is administered at a dosage of 300-800 mg/m2/time; or
capecitabine is administered at 600-700 mg/m2/time; and more preferably, 625 mg/m2/time.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of 5-fluorouracil or a prodrug or active metabolite thereof is 50-70 mg/kg/time;
preferably, 5-fluorouracil is administered at a dosage of 50-70 mg/kg/time;
and more preferably, the administration dosage of 5-fluorouracil is 50-60 mg/kg/time.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of oxaliplatin or a prodrug or active metabolite thereof is 50-300 mg/m2/time;
preferably, oxaliplatin is administered at 100-200 mg/m2/time; and more preferably, oxaliplatin is administered at 130 mg/m2/time.

### Claim 11 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the administration dosage of oxaliplatin or a prodrug or active metabolite thereof is 1-10 mg/kg/time; and preferably, oxaliplatin is administered at 1 to 5 mg/kg/time.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the antibody is a humanized antibody or a chimeric antibody.

### Claim 13 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the antibody that specifically recognizes CLDN18 comprises:
HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17, 40, or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 shown in the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 shown in the amino acid sequence of SEQ ID NO: 38, LCDR3 shown in the amino acid sequence of SEQ ID NO: 39; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 22, HCDR2 shown in the amino acid sequence of SEQ ID NO: 23, HCDR3 shown in the amino acid sequence of SEQ ID NO: 24, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 25, LCDR2 shown in the amino acid sequence of SEQ ID NO: 26, LCDR3 shown in the amino acid sequence of SEQ ID NO: 27; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 28, HCDR2 shown in the amino acid sequence of SEQ ID NO: 29, HCDR3 shown in the amino acid sequence of SEQ ID NO: 30, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 31, LCDR2 shown in the amino acid sequence of SEQ ID NO: 32, LCDR3 shown in the amino acid sequence of SEQ ID NO: 33; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 43, HCDR2 shown in the amino acid sequence of SEQ ID NO: 44, HCDR3 shown in the amino acid sequence of SEQ ID NO: 45, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 46, LCDR2 shown in the amino acid sequence of SEQ ID NO: 47, LCDR3 shown in the amino acid sequence of SEQ ID NO: 48; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 49, HCDR2 shown in the amino acid sequence of SEQ ID NO: 50, HCDR3 shown in the amino acid sequence of SEQ ID NO: 51, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 52, LCDR2 shown in the amino acid sequence of SEQ ID NO: 53, LCDR3 shown in the amino acid sequence of SEQ ID NO: 54;
preferably, the antibody that specifically recognizes CLDN18 comprises:
HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17 or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 shown in the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 shown in the amino acid sequence of SEQ ID NO: 38, LCDR3 shown in the amino acid sequence of SEQ ID NO: 39; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 43, HCDR2 shown in the amino acid sequence of SEQ ID NO: 44, HCDR3 shown in the amino acid sequence of SEQ ID NO: 45, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 46, LCDR2 shown in the amino acid sequence of SEQ ID NO: 47, LCDR3 shown in the amino acid sequence of SEQ ID NO: 48.

### Claim 14 (depends on 13)

The method of claim 13, wherein the antibody that specifically recognizes CLDN18 comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 2, 9 or 10 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 1; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 7; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 4 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 3; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 6 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 5; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56;
preferably, the antibody that specifically recognizes CLDN18 comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 2 or 10 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 1; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 7; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56;
and more preferably, the antibody comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antibody is selected from:
(a) the heavy chain encoded by the nucleotide sequence shown in SEQ ID NO: 59 and the light chain encoded by the nucleotide sequence shown in SEQ ID NO: 60; or,
(b) the heavy chain amino acid sequence shown in SEQ ID NO: 64 and the light chain amino acid sequence shown in SEQ ID NO: 63.

### Claim 16 (depends on 1)

The method of claim 1, wherein the taxanes are selected from the group consisting of paclitaxel, albumin-bound paclitaxel and docetaxel; and preferably, albumin-bound paclitaxel.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of claims 1-16, wherein the CLDN18-positive tumor includes: gastric cancer, pancreatic cancer, esophageal cancer and lung cancer; and preferably, gastric cancer.

### Claim 18

A combination of kits for treating a CLDN18-positive tumor, wherein the combination of kits includes kit A and kit B, the kit A includes an antibody that specifically recognizes CLDN18, the kit B includes chemotherapeutic drugs, and the chemotherapeutic drugs are: 5-fluorouracil or a prodrug or active metabolite thereof, oxaliplatin or a prodrug or active metabolite thereof; or 5-fluorouracil or a prodrug or active metabolite thereof, oxaliplatin or a prodrug or active metabolite thereof, and taxanes;
Preferably, the chemotherapeutic drugs are:
5-fluorouracil or a prodrug thereof, oxaliplatin or a prodrug thereof; or 5-fluorouracil or a prodrug thereof, oxaliplatin or a prodrug thereof, and taxanes;
And more preferably, the prodrug of 5-fluorouracil is capecitabine.

### Claim 19 (depends on 18)

The combination of kits of claim 18, wherein the antibody that specifically recognizes CLDN 18 in the kit A specifically recognizes CLDN 18.2; and preferably, the antibody that specifically recognizes CLDN 18 does not recognizes CLDN 18.1.

### Claim 20 (depends on 18, 19)

The combination of kits of claim 18 or 19, wherein the kit A and the kit B are administered without a particular order.

### Claim 21 (depends on 20)

The combination of kits of claim 20, wherein the kit B is administered, and then the kit A is administered.

### Claim 22 (depends on 21)

The combination of kits of claim 21, wherein the kit A and the kit B are administered on the same day; or the kit A is administered at least one day after the kit B.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of the kit A is 500-1200 mg/m2/time; preferably, 500-1000 mg/m2/time; more preferably, 500-900 mg/m2/time; and more preferably, 600-800 mg/m2/time.

### Claim 24 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of kit A is 20-300 mg/kg/time; preferably, 20-100 mg/kg/time; and more preferably, 20-50 mg/kg/time.

### Claim 25 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of 5-fluorouracil or a prodrug or active metabolite thereof is 300-900 mg/m2/time;
Preferably, 5-fluorouracil is administered at a dosage of 300-800 mg/m2/time; or
capecitabine is administered at 600-700 mg/m2/time; and preferably, 625 mg/m2/time.

### Claim 26 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of 5-fluorouracil or a prodrug or active metabolite thereof is 50-70 mg/kg/time;
preferably, 5-fluorouracil is administered at a dosage of 50-70 mg/kg/time;
and more preferably, 5-fluorouracil is administered at a dosage of 50-60 mg/kg/time.

### Claim 27 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of oxaliplatin or a prodrug or active metabolite thereof is 50-300 mg/m2/time;
preferably, oxaliplatin is administered at a dosage of 100-200 mg/m2/time;
and more preferably, oxaliplatin is administered at a dosage of 130 mg/m2/time.

### Claim 28 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the administration dosage of oxaliplatin or a prodrug or active metabolite thereof is 1-10 mg/kg/time; and preferably, oxaliplatin is administered at a dosage of 1 to 5 mg/kg/time.

### Claim 29 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the antibody that specifically recognizes CLDN18 is a humanized antibody or a chimeric antibody.

### Claim 30 (depends on 18, 19, 20, 21, 22)

The combination of kits of any one of claims 18-22, wherein the antibody that specifically recognizes CLDN18 comprises:
HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17, 40, or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 shown in the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 shown in the amino acid sequence of SEQ ID NO: 38, LCDR3 shown in the amino acid sequence of SEQ ID NO: 39; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 22, HCDR2 shown in the amino acid sequence of SEQ ID NO: 23, HCDR3 shown in the amino acid sequence of SEQ ID NO: 24, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 25, LCDR2 shown in the amino acid sequence of SEQ ID NO: 26, LCDR3 shown in the amino acid sequence of SEQ ID NO: 27; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 28, HCDR2 shown in the amino acid sequence of SEQ ID NO: 29, HCDR3 shown in the amino acid sequence of SEQ ID NO: 30, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 31, LCDR2 shown in the amino acid sequence of SEQ ID NO: 32, LCDR3 shown in the amino acid sequence of SEQ ID NO: 33; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 43, HCDR2 shown in the amino acid sequence of SEQ ID NO: 44, HCDR3 shown in the amino acid sequence of SEQ ID NO: 45, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 46, LCDR2 shown in the amino acid sequence of SEQ ID NO: 47, LCDR3 shown in the amino acid sequence of SEQ ID NO: 48; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 49, HCDR2 shown in the amino acid sequence of SEQ ID NO: 50, HCDR3 shown in the amino acid sequence of SEQ ID NO: 51, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 52, LCDR2 shown in the amino acid sequence of SEQ ID NO: 53, LCDR3 shown in the amino acid sequence of SEQ ID NO: 54;
And preferably, the antibody that specifically recognizes CLDN18 comprises:
HCDR1 shown in the amino acid sequence of SEQ ID NO: 16, HCDR2 shown in the amino acid sequence of SEQ ID NO: 17 or 41, HCDR3 shown in the amino acid sequence of SEQ ID NO: 18, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 19, LCDR2 shown in the amino acid sequence of SEQ ID NO: 20, LCDR3 shown in the amino acid sequence of SEQ ID NO: 21; or
HCDR1 shown in the amino acid sequence of SEQ ID NO: 34, HCDR2 shown in the amino acid sequence of SEQ ID NO: 35 or 42, HCDR3 shown in the amino acid sequence of SEQ ID NO: 36, and LCDR1 shown in the amino acid sequence of SEQ ID NO: 37, LCDR2 shown in the amino acid sequence of SEQ ID NO: 38, LCDR3 shown in the amino acid sequence of SEQ ID NO: 39.

### Claim 31 (depends on 30)

The combination of kits of claim 30, wherein the antibody that specifically recognizes CLDN18 comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 2, 9 or 10 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 1; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 7; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 4 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 3; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 6 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 5; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 57 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 58;
preferably, the antibody that specifically recognizes CLDN18 comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 2 or 10 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 1; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 8 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 7; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 14 or 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56;
and more preferably, the antibody comprises:
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 12 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 11; or
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 15 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 13;
the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 55 and the light chain variable region shown in the amino acid sequence of SEQ ID NO: 56.

### Claim 32 (depends on 31)

The combination of kits of claim 31, wherein the antibody is selected from:
(a) the heavy chain encoded by the nucleotide sequence shown in SEQ ID NO: 59 and the light chain encoded by the nucleotide sequence shown in SEQ ID NO: 60; or
(b) the heavy chain amino acid sequence shown in SEQ ID NO: 64 and the light chain amino acid sequence shown in SEQ ID NO: 63.

### Claim 33 (depends on 18)

The combination of kits of claim 18, wherein the taxanes in the kit B are selected from the group consisting of paclitaxel, albumin-bound paclitaxel and docetaxel; and preferably, albumin-bound paclitaxel.

### Claim 34 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The combination of kits of any one of claims 18-33, wherein the CLDN18-positive tumor includes: gastric cancer, pancreatic cancer, esophageal cancer and lung cancer.

### Claim 35

A pharmaceutical composition for treating a CLDN18-positive tumor, wherein the pharmaceutical composition comprises an antibody that specifically recognizes CLDN18 and chemotherapeutic drugs, and the chemotherapeutic drugs are 5-fluorouracil or a prodrug or active metabolite thereof, oxaliplatin or a prodrug or active metabolite thereof; or, 5-fluorouracil or a prodrug or active metabolite thereof, oxaliplatin or a prodrug or active metabolite thereof, and taxanes, as described in any one of preceding claims; and the antibody that specifically recognizes CLDN18 is the antibody as described in any one of preceding claims.

### Claim 36 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Use of the combination of kits of any one of claims 18-34 or the pharmaceutical composition of claim 35 in the preparation of a medicament for treating a CLDN18-positive tumor.

### Claim 37 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The combination of kits of any one of claims 18-34 or the pharmaceutical composition of claim 35 for use in treating a CLDN18-positive tumor.
